Nuvectis Pharma, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unaudited financial statements; amounts below are USD millions unless otherwise stated. Nuvectis is a pre-revenue oncology biopharmaceutical company developing NXP800 and NXP900.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $4.262 | $2.505 | $6.629 | $4.310 |
| General and administrative expense | $1.510 | $1.068 | $3.244 | $2.208 |
| Operating loss | $(5.772) | $(3.573) | $(9.873) | $(6.518) |
| Net loss | $(5.708) | $(3.569) | $(9.757) | $(6.512) |
| Basic and diluted loss per share | $(0.38) | $(0.28) | $(0.65) | $(0.59) |
- Cash and cash equivalents were $24.6 million at June 30, 2023, versus $20.0 million at December 31, 2022. Total current assets were $24.9 million and current liabilities $4.6 million.
- For the first six months, operating cash use was $8.9 million, financing cash inflow was $13.5 million, and investing cash flow was zero. Cash increased by $4.6 million.
- Total liabilities were $4.6 million; the filing reports no debt. The company has an accumulated deficit of $41.7 million. Profitability and operating margins are not applicable because the company has no product revenue and incurred operating losses.
Changes versus prior comparable periods
- Q2 R&D expense rose 70% year over year, chiefly due to NXP900 licensing expense, higher manufacturing costs for clinical programs, increased employee compensation, and higher clinical-trial costs. Q2 G&A expense increased 41%, primarily from public-company professional services and compensation.
- First-half operating cash use increased from $5.6 million to $8.9 million. Net financing cash flow was similar to the prior-year period, but its sources differed: 2023 included warrant and option exercises and ATM sales; 2022 included IPO proceeds.
- Cash increased despite the larger operating loss, supported by $13.5 million of financing inflows. Share count increased to 17,221,113 at June 30 from 15,190,720 at December 31, 2022.
Outlook, risks, and notable items
- Management stated that June 30 cash was expected to fund planned operations for at least 12 months from the financial-statement issuance date. The company expects expenses to rise as clinical and preclinical programs advance and says additional capital will be needed to complete development through regulatory and marketing approval.
- NXP800’s Phase 1b expansion in platinum-resistant, ARID1a-mutated ovarian carcinoma began in April 2023; the FDA granted the program Fast Track Designation in December 2022. The FDA cleared the NXP900 IND in May 2023, enabling its planned Phase 1 program.
- Funding remains a key risk: additional financing may not be available on acceptable terms. Failure to obtain sufficient capital could delay, reduce, or terminate development or other operations; equity financing could dilute existing holders.
- The company reported up to $22.0 million in pre-approval milestones and up to $178 million in additional regulatory and commercial milestones under the NXP800 license, plus tiered royalties. For NXP900, it reported up to $45.5 million in pre-approval milestones and up to $279.6 million in regulatory and commercial milestones, plus tiered royalties and a fundraising payment obligation. These contingent amounts were not accrued.
- R&D support commitments included $0.9 million with ICR, of which the company expected to expense the remaining $0.2 million in Q3 2023, and up to $754,000 with the University of Edinburgh. No contingent liabilities were reported, and no material legal matters were pending as of the report date.
- The company had a shelf registration capacity of up to $150 million, including an ATM program of up to $40 million. By June 30, it had sold 188,970 ATM shares for $3.1 million net proceeds.
Important facts for investors to verify
- Whether clinical progress, trial costs, and manufacturing spending for NXP800 and NXP900 track management’s plans.
- Cash burn and financing needs against the stated minimum 12-month runway, including any subsequent capital raises or changes in spending assumptions.
- Potential dilution from the ATM, outstanding warrants and options, and restricted stock awards.
- The timing and potential cash impact of license milestones, research-support obligations, and royalties, which depend on future events.
- Whether the reported clinical and regulatory plans produce safety, efficacy, and regulatory outcomes sufficient to advance the programs.